
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Limosilactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Limosilactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 24, 2025
Lead Product(s) : Limosilactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials | CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic
Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 23, 2022
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials | CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus gasseri BGP345A
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : BioFortis
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
Details : Lactobacillus gasseri BGP345A is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Induced Constipation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Lactobacillus gasseri BGP345A
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : BioFortis
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BGP-014
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
Details : BGP-014 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 12, 2021
Lead Product(s) : BGP-014
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotics on Testosterone in Men
Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Biogaia Protectis
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lactobacillus Reuteri DSM 17938 in Gut Microbiota Development in Infant Born by Caesarean Section
Details : Biogaia Protectis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Dysbiosis.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 18, 2018
Lead Product(s) : Biogaia Protectis
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Probiotic
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Region Skane
Deal Size : Inapplicable
Deal Type : Inapplicable
Probiotics to Treat "Inflammatory Depression"
Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 06, 2018
Lead Product(s) : Probiotic
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Region Skane
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Probiotic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
December 08, 2017
Lead Product(s) : Probiotic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus reuteri DSM17938
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness of Probiotic Supplementation on Crying Time in Infantile Colic
Details : Lactobacillus reuteri DSM17938 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 10, 2017
Lead Product(s) : Lactobacillus reuteri DSM17938
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All